Altheus is currently enrolling patients at centers across the United States in ZA201, a clinical study of Zoenasa in patients with left-sided ulcerative colitis.
Zoenasa is a fixed-dose combination of mesalamine plus a second potent anti-inflammatory. In preclinical and early clinical studies, Zoenasa showed a 50-100% improvement over mesalamine alone.